472 related articles for article (PubMed ID: 31118692)
1. KIAA1429 regulates the migration and invasion of hepatocellular carcinoma by altering m6A modification of ID2 mRNA.
Cheng X; Li M; Rao X; Zhang W; Li X; Wang L; Huang G
Onco Targets Ther; 2019; 12():3421-3428. PubMed ID: 31118692
[TBL] [Abstract][Full Text] [Related]
2. KIAA1429 facilitates metastasis via m6A-YTHDC1-dependent RND3 down-regulation in hepatocellular carcinoma cells.
Shan M; Liu D; Sun L; Yang M; He M; Zhang Y; Xiang L; Lu L; He H; Niu D; Chen L; Li S; Chen A; He F; Wang Y; Lian J
Cancer Lett; 2024 Mar; 584():216598. PubMed ID: 38224863
[TBL] [Abstract][Full Text] [Related]
3. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3.
Lan T; Li H; Zhang D; Xu L; Liu H; Hao X; Yan X; Liao H; Chen X; Xie K; Li J; Liao M; Huang J; Yuan K; Zeng Y; Wu H
Mol Cancer; 2019 Dec; 18(1):186. PubMed ID: 31856849
[TBL] [Abstract][Full Text] [Related]
4. KIAA1429 mediates epithelial mesenchymal transition in sorafenib-resistant hepatocellular carcinoma through m6A methylation modification.
Kuang Y; Cheng Y; Wang J; Li H; Cao X; Wang Y
Cancer Med; 2023 Mar; 12(6):7222-7233. PubMed ID: 36420693
[TBL] [Abstract][Full Text] [Related]
5. KIAA1429 Induces m6A Modification of LINC01106 to Enhance the Malignancy of Lung Adenocarcinoma Cells via the JAK/STAT3 Pathway.
Xu D; Wang Z; Li F
Crit Rev Immunol; 2024; 44(6):49-61. PubMed ID: 38848293
[TBL] [Abstract][Full Text] [Related]
6. KIAA1429 promotes the progression of lung adenocarcinoma by regulating the m6A level of MUC3A.
Zhao W; Xie Y
Pathol Res Pract; 2021 Jan; 217():153284. PubMed ID: 33249400
[TBL] [Abstract][Full Text] [Related]
7. KIAA1429 Promotes Nasopharyngeal Carcinoma Progression by Mediating m6A Modification of PTGS2.
Wu L; Zhou Y; Fu J
Crit Rev Immunol; 2023; 43(4):15-27. PubMed ID: 37830191
[TBL] [Abstract][Full Text] [Related]
8. Gene amplification-driven RNA methyltransferase KIAA1429 promotes tumorigenesis by regulating BTG2 via m6A-YTHDF2-dependent in lung adenocarcinoma.
Zhang C; Sun Q; Zhang X; Qin N; Pu Z; Gu Y; Yan C; Zhu M; Dai J; Wang C; Li N; Jin G; Ma H; Hu Z; Zhang E; Tan F; Shen H
Cancer Commun (Lond); 2022 Jul; 42(7):609-626. PubMed ID: 35730068
[TBL] [Abstract][Full Text] [Related]
9. Inhibin A contributes to the tumorigenesis of oral squamous cell carcinoma by KIAA1429-mediated m6A modification.
Chen X; Fan R
J Oral Pathol Med; 2024 Apr; 53(4):266-274. PubMed ID: 38531807
[TBL] [Abstract][Full Text] [Related]
10. KIAA1429-mediated RXFP1 attenuates non-small cell lung cancer tumorigenesis via N6-methyladenosine modification.
Zhang Z; Guo J; Gong C; Wu S; Sun Y
Cancer Biomark; 2024 Feb; ():. PubMed ID: 38427468
[TBL] [Abstract][Full Text] [Related]
11. KIAA1429-mediated m6A modification of CHST11 promotes progression of diffuse large B-cell lymphoma by regulating Hippo-YAP pathway.
Chen X; Lu T; Cai Y; Han Y; Ding M; Chu Y; Zhou X; Wang X
Cell Mol Biol Lett; 2023 Apr; 28(1):32. PubMed ID: 37076815
[TBL] [Abstract][Full Text] [Related]
12. N6-methyladenosine associated prognostic model in hepatocellular carcinoma.
Huang H; Bai Y; Lu X; Xu Y; Zhao H; Sang X
Ann Transl Med; 2020 May; 8(10):633. PubMed ID: 32566570
[TBL] [Abstract][Full Text] [Related]
13. KIAA1429 is a potential prognostic marker in colorectal cancer by promoting the proliferation via downregulating WEE1 expression in an m6A-independent manner.
Ma L; Lin Y; Sun SW; Xu J; Yu T; Chen WL; Zhang LH; Guo YC; Wang YW; Chen T; Wei JF; Zhu LJ
Oncogene; 2022 Jan; 41(5):692-703. PubMed ID: 34819634
[TBL] [Abstract][Full Text] [Related]
14. KIAA1429 facilitates progression of hepatocellular carcinoma by modulating m6A levels in HPN.
Meng Y; Yang W; Li J; Chai W
Heliyon; 2023 Nov; 9(11):e22084. PubMed ID: 38058614
[TBL] [Abstract][Full Text] [Related]
15. The biological function of m6A methyltransferase KIAA1429 and its role in human disease.
Zhang X; Li MJ; Xia L; Zhang H
PeerJ; 2022; 10():e14334. PubMed ID: 36389416
[TBL] [Abstract][Full Text] [Related]
16. KIAA1429 regulates cell proliferation by targeting c-Jun messenger RNA directly in gastric cancer.
Miao R; Dai CC; Mei L; Xu J; Sun SW; Xing YL; Wu LS; Wang MH; Wei JF
J Cell Physiol; 2020 Oct; 235(10):7420-7432. PubMed ID: 32052427
[TBL] [Abstract][Full Text] [Related]
17. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
[TBL] [Abstract][Full Text] [Related]
18. m
Zhou Y; Pei Z; Maimaiti A; Zheng L; Zhu Z; Tian M; Zhou Z; Tan F; Pei Q; Li Y; Liu W
Cell Death Discov; 2022 Feb; 8(1):83. PubMed ID: 35217651
[TBL] [Abstract][Full Text] [Related]
19. SMC1A regulated by KIAA1429 in m6A-independent manner promotes EMT progress in breast cancer.
Zhang X; Dai XY; Qian JY; Xu F; Wang ZW; Xia T; Zhou XJ; Li XX; Shi L; Wei JF; Ding Q
Mol Ther Nucleic Acids; 2022 Mar; 27():133-146. PubMed ID: 34976433
[TBL] [Abstract][Full Text] [Related]
20. The functions and prognostic values of m6A RNA methylation regulators in thyroid carcinoma.
Yu ZH; Feng ST; Zhang D; Cao XC; Yu Y; Wang X
Cancer Cell Int; 2021 Jul; 21(1):385. PubMed ID: 34281544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
